New drug combo targets Hard-to-Treat cancers with gene mutation
NCT ID NCT06496568
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a drug called inavolisib, alone or with atezolizumab, in people with cancers that have a specific change in the PIK3CA gene. The study includes patients with head and neck cancer that has returned or spread. The main goals are to check safety and see if the tumors shrink.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BC Cancer Vancouver Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Vanderbilt-Ingram Cancer Ctr
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?